Cancer and Molecular Therapies

Dr. Maayan Gal

Dr. Gal is a faculty member in the Department of Oral Biology at the School of Dental Medicine. He completed his PhD studies at the Department of Chemical Physics at the Weizmann Institute of Science and was an HFSP postdoctoral fellow at the Harvard Medical School. He ran an independent lab at Migal in northern Israel. Gal co -founded two biotech companies dealing with food and Ag.Chem protein modulators.

https://maayaangaal.wixsite.com /galma

Protein modulators for therapy

Dr. Gal focuses on the discovery and development of novel protein modulators as the basis for new therapeutics . Of main interest are the challenging targets belonging to the biological space of protein -protein interactions (PPIs). For this purpose, we are integrating cutting -edge computational, biophysical and cellular biology tools . We are focused on the interaction of calcineurinNFAT proteins, known as the T-cell activation switch, as the basis for developing new immunosuppressant and on immune checkpoint receptors function The T-cell inhibition switch is the basis for developing new therapeutics for inflammation and cancer.